DHGAF yields 2.78% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, DHGAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DHGAF + JNJ for your $10,000?
Domain Holdings Australia Limited engages in the real estate media and technology services business in Australia. The company operates through Core Digital, Consumer Solutions, and Print segments. It offers residential, commercial, and rural property marketing services through desktop, mobile, and social platforms, as well as print magazines; and search and valuation tools and insights to buyers, sellers, investors, renters, governments, and agents. The company also provides a digital display platform for brands to advertise for consumer audiences; and commercial real estate services, including digital subscription, depth listings, and display advertising for a range of sectors, such as industrial, office, retail, and developers. In addition, it offers agent solutions that provides a platform of property data, real time agent supplies digital agency agreements, auction solutions and contracts, and Homepass that delivers a registration tool and database for property open-for-inspections. Further, the company provides a property data solution to agents, consumers, government, financial institutions, and corporates. Additionally, it publishes real estate newspapers and magazines; and provides property lifecycle services, including home loans, insurance, trade services, and residential utilities connections. The company was incorporated in 2000 and is headquartered in Pyrmont, Australia. Domain Holdings Australia Limited is a subsidiary of Nine Entertainment Co. Holdings Limited.
Full DHGAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.